Envíos recientes

The potential benefit of encorafenib plus cetuximab with chemotherapy compared with standard of care in people with BRAF V600E-mutant metastatic colorectal cancer in the BREAKWATER study: a plain language summary

Yoshino, Takayuki; Van Cutsem, Eric; Eng, Cathy; Kim, Tae Won; Wasan, Harpreet; Kopetz, Scott; Tabernero, Josep (Taylor & Francis, 2025)

Long-Term Transfusion Independence with Luspatercept Versus Epoetin Alfa in Erythropoiesis-Stimulating Agent-Naive, Lower-Risk Myelodysplastic Syndromes in the COMMANDS Trial

Garcia-Manero, Guillermo; SANTINI, VALERIA; Zeidan, Amer; Komrokji, Rami S.; Pozharskaya, Veronika; Rose, Shelonitda; VALCARCEL, DAVID (Adis, 2025-07)

Phospho-RPA2 predicts response to platinum and PARP inhibitors in homologous recombination–proficient ovarian cancer

Schab, Angela; Compadre, Amanda; Drexler, Rebecca; loeb, Megan; Rodriguez, Kevin; Brill, Joshua; Serra, Violeta (American Society for Clinical Investigation, 2025-05-20)

First-in-human study of FAZ053, an anti-programmed death-ligand 1 (anti-PD-L1) monoclonal antibody, alone and in combination with spartalizumab (anti-PD-1), in patients with advanced malignancies

Tan, David; Martín Liberal, Juan Jesús; Geva, Ravit; Gucalp, Ayca; Janku, Filip; Takahashi, Shunji (Elsevier, 2025-06)

Association of radiation-induced normal tissue toxicity with a high genetic risk for rheumatoid arthritis

Mcwilliam, Alan; Marshall, Deborah; Kerns, Sarah; Barnett, Gill; Vega, Ana; Kapouranis, Thodori; Gutiérrez-Enríquez, Sara (Oxford University Press, 2025-05)

Scientia. Depósito de Información Digital del Departamento de Salud

Vall d'Hebron Institut d'Oncologia - VHIO: Envíos recientes

The potential benefit of encorafenib plus cetuximab with chemotherapy compared with standard of care in people with BRAF V600E-mutant metastatic colorectal cancer in the BREAKWATER study: a plain language summary

Long-Term Transfusion Independence with Luspatercept Versus Epoetin Alfa in Erythropoiesis-Stimulating Agent-Naive, Lower-Risk Myelodysplastic Syndromes in the COMMANDS Trial

Phospho-RPA2 predicts response to platinum and PARP inhibitors in homologous recombination–proficient ovarian cancer

First-in-human study of FAZ053, an anti-programmed death-ligand 1 (anti-PD-L1) monoclonal antibody, alone and in combination with spartalizumab (anti-PD-1), in patients with advanced malignancies

Association of radiation-induced normal tissue toxicity with a high genetic risk for rheumatoid arthritis

Scientia. Depósito de Información Digital del Departamento de Salud

Vall d'Hebron Institut d'Oncologia - VHIO: Envíos recientes

The potential benefit of encorafenib plus cetuximab with chemotherapy compared with standard of care in people with BRAF V600E-mutant metastatic colorectal cancer in the BREAKWATER study: a plain language summary ﻿

Long-Term Transfusion Independence with Luspatercept Versus Epoetin Alfa in Erythropoiesis-Stimulating Agent-Naive, Lower-Risk Myelodysplastic Syndromes in the COMMANDS Trial ﻿

Phospho-RPA2 predicts response to platinum and PARP inhibitors in homologous recombination–proficient ovarian cancer ﻿

First-in-human study of FAZ053, an anti-programmed death-ligand 1 (anti-PD-L1) monoclonal antibody, alone and in combination with spartalizumab (anti-PD-1), in patients with advanced malignancies ﻿

Association of radiation-induced normal tissue toxicity with a high genetic risk for rheumatoid arthritis ﻿

The potential benefit of encorafenib plus cetuximab with chemotherapy compared with standard of care in people with BRAF V600E-mutant metastatic colorectal cancer in the BREAKWATER study: a plain language summary

Long-Term Transfusion Independence with Luspatercept Versus Epoetin Alfa in Erythropoiesis-Stimulating Agent-Naive, Lower-Risk Myelodysplastic Syndromes in the COMMANDS Trial

Phospho-RPA2 predicts response to platinum and PARP inhibitors in homologous recombination–proficient ovarian cancer

First-in-human study of FAZ053, an anti-programmed death-ligand 1 (anti-PD-L1) monoclonal antibody, alone and in combination with spartalizumab (anti-PD-1), in patients with advanced malignancies

Association of radiation-induced normal tissue toxicity with a high genetic risk for rheumatoid arthritis